Adavanced Glycated Endproducts and Development of CAD

NCT02089360 | Unknown DMC

• 1 other identifier: RJH20140311
• Study Type: observational
• Target: 10,000
• Locations: 1 country
• Sites: 1

Brief Summary

Blood sample is prospectively taken from consecutive patients underwent coronary angiogram in our center, after getting informed consent from the patients. Serum level of advanced glycation end products (AGEs) was measured and the clinical features of patients (including angiographic results) were entered into our database. Clinical follow-up was performed for all patients, and the relationship between AGEs and paitents' outcome were analyzed. Further intervention will be adjusted according to the results,including clinical and basic research in lab.

Conditions

Atherosclerosis; Inflammation

Keywords

Advanced glycation end product; coronary; atherosclerosis; inflammation; outcome

Outcome Measures

Primary Outcomes (1)

• MACE

  including death, occurrence of myocardial infarction, and coronary revascularization

  5-year

Secondary Outcomes (1)

• progression in coronary atherosclerosis

  5-year

Other Outcomes (1)

• Serum level of AGEs

  baseline

Eligibility Criteria

• Age: 18 Years - 90 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

patients underwent coronary angiogram

You may qualify if:

• patients underwent coronary angiogram for suspected coronary artery disease and potential percutaneous coronary intervention

You may not qualify if:

• patients underwent coronary angiogram for other reasons, including pre-surgery examination
• patients with severe co-morbidity, and life expectancy less than one-year

Sponsors & Collaborators

• Shanghai Jiao Tong University School of Medicine: lead

Study Sites (1)

Ruijin Hospital, Shanghai Jiaotong University School of Medicine

Shanghai, Shanghai Municipality, 200025, China

RECRUITING

Related Publications (3)

• Yang CD, Shen Y, Lu L, Yang ZK, Hu J, Zhang RY, Shen WF, Ding FH, Wang XQ. Visit-to-visit HbA1c variability is associated with in-stent restenosis in patients with type 2 diabetes after percutaneous coronary intervention. Cardiovasc Diabetol. 2020 Sep 4;19(1):133. doi: 10.1186/s12933-020-01111-7.

  PMID: 32887588 DERIVED

• Yang CD, Shen Y, Ding FH, Yang ZK, Hu J, Shen WF, Zhang RY, Lu L, Wang XQ. Visit-to-visit fasting plasma glucose variability is associated with left ventricular adverse remodeling in diabetic patients with STEMI. Cardiovasc Diabetol. 2020 Sep 2;19(1):131. doi: 10.1186/s12933-020-01112-6.

  PMID: 32878604 DERIVED

• Yang CD, Shen Y, Lu L, Ding FH, Yang ZK, Zhang RY, Shen WF, Jin W, Wang XQ. Insulin resistance and dysglycemia are associated with left ventricular remodeling after myocardial infarction in non-diabetic patients. Cardiovasc Diabetol. 2019 Aug 7;18(1):100. doi: 10.1186/s12933-019-0904-3.

  PMID: 31391045 DERIVED

Biospecimen

Retention: SAMPLES WITH DNA

Blood sample is taken for all patients underwent coronary angiogram after getting informed consent, and stored in requested condition, for measuring serum levels of different kinds of factors.

MeSH Terms

Conditions

Atherosclerosis; Inflammation

Condition Hierarchy (Ancestors)

Arteriosclerosis; Arterial Occlusive Diseases; Vascular Diseases; Cardiovascular Diseases; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Central Study Contacts

Qi Zhang, PhD

CONTACT

86-21-64370045; rjheart@gmail.com

Wei Feng Shen, PhD

CONTACT

86-21-64370045; rjshenweifeng@gmail.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 5 Years
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Director, Cardiac Catheterization Lab

Study Record Dates

• First Submitted: March 13, 2014
• First Posted: March 17, 2014
• Study Start: January 1, 2014
• Primary Completion: January 1, 2016
• Last Updated: March 17, 2014

Record last verified: 2014-03

Locations

CN (1)